ResApp Health : COVID-19 Investor Presentation

nal use only

COVID-19

Investor briefing

22 March 2022

Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not

been independently audited or verified by ResApp.

Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they

onlyare subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward- looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

The i formation in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of

certain information relating to the performance of ResApp. The information in this presentation is of a general nature and does not purport to be complete. This presentation sh uld be read in conjunction with ResApp's other periodic and continuous disclosure announcements, which are available at https://www.resapphealth.com.au/investor-

relations/asx-announcements/.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and
whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising
use
out of, or in connection with, any use or reliance on this presentation or information.
This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation
nor anything in it shall form the basis for any contract or commitment whatsoever.
All amounts in Australian dollars unless stated otherwise.
nal	2

Agenda

nal use only

COVID-19	Public	Market &
research	health	commercial
& results	context	strategy
Tony Keating	Professor	Mike Connell
CEO & Managing Director	Catherine Bennett	VP, Commercial

3

ResApp's COVID-19 scientific advisory board

nal use only

Prof. Elizabeth Talbot	Prof. Antonio Anzueto	Prof. Catherine Bennett
Geisel School of Medicine	University of Texas Health	Chair in Epidemiology
Dartmouth	San Antonio	Deakin University

Assoc. Prof. Joan Soriano	Assoc. Prof. Mark Howard	Assoc. Prof. Paul Porter
Hospital Universitario	Director of the Victorian	Curtin University & Joondalup
de la Princesa Madrid	Respiratory Support Service	Health Campus

4

COVID-19	Global stats4
• Coronavirus disease (COVID-19) is an infectious disease	Cases	Deaths
caused by the SARS-CoV-2 virus	Last 2 weeks 23.8m	72.9k

• Globally there has been >6m deaths, at a mortality rate
estimated to be x10 higher than flu2
only		Overall
• At the peak of Omicron, Australians were waiting for up to
7 days for PCR test results (after waiting in queue for up to
6 hours) and rapid antigen tests were difficult to source3
• PCR and rapid antigen tests
generally require a nasal swab as	Europe
use
shown (right)	Americas
• Rapid antigen tests are widely used	South-East Asia
to screen and detect COVID-19
Western Pacific
		Eastern Mediterranean
		1
nal		Africa
1. https://www.nejm.org/doi/full/10.1056/nejmvcm2010260

2. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-disease-2019-vs-the-flu

3. https://www.theage.com.au/politics/victoria/test-samples-no-longer-suitable-after-seven-day-wait-20220108-p59ms1.html

4. https://covid19.who.int (data to 18/3/2022)

Cases Deaths

465m 6.06m

Cases by region

(confirmed)

191,842,819

149,435,827

56,667,275 36,865,816

21,478,988 8,517,888

5